Mid-Year Enforcement Roundup: Focus On Opioids, As Other Areas Lag

A recent report from law firm Gibson Dunn seems to show that the Trump administration, while aggressively pursuing opioid enforcement actions, slowed down enforcement in other areas during the first half of 2018. But important case-law developments continue.

Gavel
• Source: Shutterstock

US health-care regulatory bodies, including the Department of Justice and FDA, focused on opioid enforcement in the first half of 2018, taking the spotlight off cases involving devices and diagnostics. But device-industry legal pros found plenty to watch in the courts, where the ramifications of recent federal court rulings involving the False Claims Act (FCA) continued to play out.

That’s the key takeaway from the 2018 Mid-Year Health Care Compliance and Enforcement Update issued by law firm Gibson...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Compliance

More from Policy & Regulation

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By 

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.